Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefania Mosconi

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 10, 2015
Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyEmanuele Valtorta, Cosimo Martino, Andrea Sartore-Bianchi, et al.
Tumori|June 12, 2020
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-SMaria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2019
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal CancerFilippo Pietrantonio, Riccardo Lobefaro, Maria Antista, et al.
Journal of the National Cancer Institute|April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialStefano Cascinu, Roberto Labianca, Carlo Barone, et al.
Cancer Medicine|January 25, 2025
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic VariantsMichele Milella, Giulia Orsi, Mariacristina di Marco, et al.
BMC Cancer|April 8, 2024
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY studyMonica Niger, Federico Nichetti, Lorenzo Fornaro, et al.
BMC Cancer|May 6, 2024
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY studyMonica Niger, Federico Nichetti, Lorenzo Fornaro, et al.
The Lancet. Oncology|November 27, 2025
Total neoadjuvant therapy followed by non-operative management or surgery in stage II-III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trialAlessio Amatu, Giorgio Patelli, Maria Giulia Zampino, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 10, 2015
Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyEmanuele Valtorta, Cosimo Martino, Andrea Sartore-Bianchi, et al.
Tumori|June 12, 2020
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-SMaria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2019
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal CancerFilippo Pietrantonio, Riccardo Lobefaro, Maria Antista, et al.
Journal of the National Cancer Institute|April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialStefano Cascinu, Roberto Labianca, Carlo Barone, et al.
Cancer Medicine|January 25, 2025
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic VariantsMichele Milella, Giulia Orsi, Mariacristina di Marco, et al.
BMC Cancer|April 8, 2024
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY studyMonica Niger, Federico Nichetti, Lorenzo Fornaro, et al.
BMC Cancer|May 6, 2024
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY studyMonica Niger, Federico Nichetti, Lorenzo Fornaro, et al.
The Lancet. Oncology|November 27, 2025
Total neoadjuvant therapy followed by non-operative management or surgery in stage II-III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trialAlessio Amatu, Giorgio Patelli, Maria Giulia Zampino, et al.
Pageof 3